Publications by authors named "Kim Luley"

Claim this Profile
P
Personalized Combined Nutrition & Exercise Intervention in Newly Diagnosed Cancer Patients - a Trial Protocol.
Sebastian Theurich, Timo Niels, Hansjoerg Baurecht, Christine Welker, Annika Tomanek, Kim Luley

Future Sci OA· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Individually compounded multi-chamber vs. standardized parenteral nutrition bags in solid tumors-A randomized clinical trial (IKF-010).
Thorsten Oliver Goetze, Ralf-Dieter Hofheinz, Ingeborg Roetzer, Wolfgang Blau, Thomas Zander, Kim Barbara Luley

Clin Nutr ESPEN· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Which Immunotherapies are Standard Today? And What Side Effects Should be Expected?].
Zhala Gasimova, Cyrus Khandanpour, Kim Luley, Nikolas Christian Cornelius von Bubnoff

Zentralbl Chir· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
Michael Masetti, Salah-Eddin Al-Batran, Thorsten O Goetze, Peter Thuss-Patience, Jorge Riera Knorrenschild, Kim Barbara Luley

Int J Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.
Isabel Porth, Daniela Hirsch, Yonca Ceribas, Philip Weidner, Wilko Weichert, Kim Luley

Eur J Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential Effects of Somatostatin, Octreotide, and Lanreotide on Neuroendocrine Differentiation and Proliferation in Established and Primary NET Cell Lines: Possible Crosstalk with TGF-β Signaling.
Hendrik Ungefroren, Axel Künstner, Hauke Busch, Sören Franzenburg, Kim Luley

Int J Mol Sci· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tailored Systemic Therapy for Colorectal Cancer Liver Metastases.
Carolin Czauderna, Kim Luley, Nikolas von Bubnoff, Jens U Marquardt

Int J Mol Sci· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resection of Non-Functional Pancreatic Neuroendocrine Neoplasms-A Single-Center Retrospective Outcome Analysis.
Kirsten Lindner, Daniel Binte, Jens Hoeppner, Ulrich F Wellner, Dominik M Schulte, Kim Luley

Curr Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).
Sylvie Lorenzen, Jorge Riera Knorrenschild, Claudia Pauligk, Susanna Hegewisch-Becker, Jörg Seraphin, Kim Barbara Luley

Int J Cancer· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Comprehensive Molecular Characterization of the Pancreatic Neuroendocrine Tumor Cell Lines BON-1 and QGP-1.
Kim B Luley, Shauni B Biedermann, Axel Künstner, Hauke Busch, Sören Franzenburg

Cancers (Basel)· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Salah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, Thorsten O Goetze, Johannes Meiler, Kim Luley

Lancet· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MicroRNA analysis of gastroenteropancreatic neuroendocrine tumors and metastases.
Nadine Zimmermann, Juliana Knief, Tim Kacprowski, Pamela Lazar-Karsten, Tobias Keck, Kim Luley

Oncotarget· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Salah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, Gerald Illerhaus, Uwe M Martens, Kim B Luley

JAMA Oncol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support.
Niklas Gebauer, Harald Biersack, Ann-Cathrin Czerwinska, Janina Schemme, Tim Tristan Hardel, Kim Barbara Luley

Leuk Lymphoma· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Salah-Eddin Al-Batran, Ralf D Hofheinz, Claudia Pauligk, Hans-Georg Kopp, Georg Martin Haag, Kim Barbara Luley

Lancet Oncol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective.
Niklas Gebauer, Harald Biersack, Ann-Cathrin Czerwinska, Janina Schemme, Tim Tristan Hardel, Kim Barbara Luley

Leuk Lymphoma· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+).
Salah-Eddin Al-Batran, Claudia Pauligk, Nils Homann, Jörg T Hartmann, Markus Moehler, Kim Luley

Eur J Cancer· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel.
Nils Homann, Claudia Pauligk, Kim Luley, Thomas Werner Kraus, Hans-Peter Bruch

Int J Cancer· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Local calprotectin production in colorectal cancer and polyps--active neutrophil recruitment in carcinogenesis.
Kim Luley, Frank Noack, Hendrik Lehnert, Nils Homann

Int J Colorectal Dis· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Idiopathic thrombocytopenic purpura (Werlhof disease) and differential diagnosis from other thrombocytopenic hemorrhagic diatheses].
Kim B Luley, Thomas Wagner

Med Klin (Munich)· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis